This triallooks at the safety and performance of a transcatheter mitral valve for high-risk patients with moderate-severe and severe mitral regurgitation.
1 Primary · 0 Secondary · Reporting Duration: 30 days
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Single · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the population size of this experiment?
"A total of 15 patients that meet the eligibility criteria are required for this trial and can be recruited from two separate medical institutions: Chippenham Hospital Richmond in Virginia, and University of Pennsylvania in Philadelphia." - Anonymous Online Contributor
In what number of healthcare facilities is this trial currently taking place?
"At the present moment, 8 different clinical trial sites are operational. These locations span from Richmond to Philadelphia and Charleston with other centres scattered in between. To minimize travel time, those interested should select a facility closest to them if they choose to enroll." - Anonymous Online Contributor
Is this experiment recruiting participants currently?
"Affirmative. According to clinicaltrials.gov, this healthcare experiment is currently in need of participants and was first posted on July 14th 2020. This study has been updated as recently as October 21st 2022 and requires 15 people between 8 sites." - Anonymous Online Contributor